Leading the Next Generation of Delicious, Natural and Nutritious Food: Upfield Renamed as Flora Food Group
17.9.2024 16:00:00 CEST | Business Wire | Press release
Upfield Group B.V., global branded food champion, announces today that it has changed its name to Flora Food Group B.V. The name change is a substantial step in the company's evolution and follows a performance-driven transformation on multiple levels across the entire company.
The new name reflects Flora Food Group’s evolved purpose of delivering the next generation of delicious, natural, and nutritious food that is more affordable and more sustainable than its dairy equivalents. Capitalizing on four global megatrends (population growth, demand for dairy-alternative solutions, animal welfare concerns, and environmental regulations), Flora Food Group leads the change with products that address these trends across four growing categories - butter and spreads, creams, liquids, and cheese - offering consumers a compelling choice.
Leveraging its 150+ years of heritage and in-depth R&D expertise, Flora Food Group will seek to drive further conversion in butter, creams, liquids, and cheese, offering exciting growth opportunities for its iconic brands, local brands and professional business.
David Haines, Group CEO of Flora Food Group, commented: "The name change to Flora Food Group is an exciting and logical step in the large-scale transformation we have delivered. We have fully reinvented our company. The new name better reflects who we are, with Flora being one of our longest-standing and most popular brands loved by millions of families and professionals around the world. This name also evokes the company's rich heritage and broad portfolio. It conveys our great passion to make delicious, natural, and nutritious food, helping to nourish hundreds of millions of families every day.”
The name change will take effect immediately at the Dutch corporate level, with a phased approach across Flora Food Group’s global markets in the months ahead. Visit www.florafoodgroup.com for more information.
About Flora Food Group:
Global branded food champion Flora Food Group offers the next generation of delicious, natural, nutritious food. Our products are more affordable and more sustainable than their dairy equivalents. We offer consumers a compelling choice in four growing categories: butters and spreads, creams, liquids, and cheeses. We hold leadership positions in many of the 100 countries we operate in, with iconic brands including Flora, Becel+ProActiv, BlueBand, Country Crock, I Can’t Believe It’s Not Butter, Rama, and Violife, together with our local brands and Professional business. We have 150+ years of heritage, deep R&D expertise and a relentless commitment to delivering delicious, nutritious food. We own 14 manufacturing sites across five continents. Flora Food Group is headquartered in Amsterdam (Netherlands) and employs ~4,800 people; the company reported net sales of EUR 3.3 billion in 2023, making it the global leader in plant-based food.
This press release may contain forward-looking statements with respect to Flora Food Group’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of Flora Food Group and information currently available to the company. Flora Food Group cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Flora Food Group has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917264963/en/
Contacts
Flora Food Group Media Relations
Flora Food Group Media Relations
medialine@florafg.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom